Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 335

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Treatment of Churg‐Strauss syndrome without poor‐prognosis factors: A multicenter, prospective, randomized, open‐label study of seventy‐two patients

Open access
Ribi, Camillo, Cohen, Pascal, Pagnoux, Christian, Mahr, Alfred, Arène, Jean‐Pierre, Lauque, Dominique, Puéchal, Xavier, Letellier, Philippe, Delaval, Philippe, Cordier, Jean‐François, Guillevin, Loïc·2008·Arthritis & Rheumatism

Abstract

Objective: To assess the efficacy of systemic corticosteroids (CS) alone as first‐line treatment in patients with Churg‐Strauss syndrome (CSS) without poor‐prognosis factors, as defined by the Five‐Factors Score (FFS), and to compare the efficacy and safety of oral azathioprine (AZA) versus intravenous pulse cyclophosphamide (CYC) as adjuvant immunosuppressive therapy for treatment failure or relapse. Methods: This multicenter, prospective, randomized, open‐label therapeutic trial included 72 patients with newly diagnosed CSS (FFS of 0) treated with CS alone. At treatment failure or relapse, patients were randomized to receive 6 months of oral AZA or 6 pulses of CYC. Analyses were performed according to an intent‐to‐treat strategy. Results: The mean ± SD followup was 56.2 ± 31.7 months. Among the 72 patients studied, 93% achieved remission with CS therapy alone, and 35% relapsed, mainly during the first year of treatment. Among the 19 patients randomized to additional immunosuppression because of treatment failure or relapse, 5 of 10 receiving AZA and 7 of 9 receiving pulse CYC achieved remission, but the difference was not statistically significant. Survival rates in all patients at 1 and 5 years were 100% and 97%, respectively. At the end of followup, 79% of the patients whose disease was in remission required low‐dose CS therapy, mainly to control respiratory disease. CS‐related adverse events were observed in 31% of the 72 patients. Conclusion: In CSS patients with an FFS of 0, survival was excellent, confirming the predictive value of the FFS in this disease. First‐line therapy with CS achieved remission in most patients, but relapses were common, and one‐third of them required additional immunosuppressive therapy. AZA or pulse CYC was fairly effective in treating CS‐resistant disease or major relapses. Over the long term, most patients continued to take oral CS, which might explain the high rate of CS‐related adverse events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.23198

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 335

Metadata

Authors
Ribi, C., Cohen, P., Pagnoux, C., Mahr, A., Arène, J., Lauque, D., Puéchal, X., Letellier, P., Delaval, P., Cordier, J., & Guillevin, L.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2008-01-31
Volume
58
Issue
2
Pages
586-594
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2082874877
Cited by
335
References
18
FWCI
15.58
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Churg‐Strauss syndrome without poor‐prognosis factors: A multicenter, prospective, randomized, open‐label study of seventy‐two patients. https://app.cochat.ai/papers/10.1002/art.23198
The paper
Ribi, C., Cohen, P., Pagnoux, C., Mahr, A., Arène, J., Lauque, D., Puéchal, X., Letellier, P., Delaval, P., Cordier, J., & Guillevin, L. (2008). Treatment of Churg‐Strauss syndrome without poor‐prognosis factors: A multicenter, prospective, randomized, open‐label study of seventy‐two patients. Arthritis & Rheumatism. https://doi.org/10.1002/art.23198

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.